Literature DB >> 22537282

Current approaches in tamper-resistant and abuse-deterrent formulations.

David J Mastropietro1, Hossein Omidian.   

Abstract

CONTEXT: The escalating abuse of prescription drugs has recently spawned the development of novel drug formulations resistant to various methods of tampering and misuse.
OBJECTIVE: The intent of this paper is to provide an overview and classification system of formulation approaches, developed to produce what most refer to as abuse-deterrent or tamper-resistant dosage forms.
METHODS: A comprehensive literature search was conducted within Embase™ and Medline using key words "abuse deterrentâ and "tamper resistantâ to identify relevant technologies. Only issued patents were examined using the phrase "abuse deterrent compositionâ searched through PatFT from the United States Patent and Trademark Office. Current information from press releases and product innovator websites was obtained for additional data.
RESULTS: Identified formulation approaches were organized into two categories, physical approaches and chemical approaches. Physical approaches were subcategorized into solids, gels or non-intentionals, while chemical approaches were further broken down into agonists/antagonists, aversives, or metabolics. Among issued patents specifying an abuse-deterrent method, nine diverse approaches were found. Most formulations under development combined approaches, and utilized proprietary technologies from pharmaceutical manufacturers.
CONCLUSIONS: Prodrug and agonist/antagonist formulations are popular in marketed products, while solid and gel approaches are more recent additions. However, the inclusion of aversive agents or enzyme inhibitors in a product is proving to be more difficult to develop. Overall, detailed formulation and manufacturing methods still remain rather elusive to protect public health. Moreover, these innovative formulations are mostly untried in the general population and their abuse deterring effects has yet to be proven.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22537282     DOI: 10.3109/03639045.2012.680468

Source DB:  PubMed          Journal:  Drug Dev Ind Pharm        ISSN: 0363-9045            Impact factor:   3.225


  12 in total

1.  Effects of ethanol on the pharmacokinetics of extended-release oxycodone with sequestered naltrexone (ALO-02).

Authors:  Bimal K Malhotra; Kyle Matschke; Qiang Wang; Candace Bramson; Joanne Salageanu
Journal:  Clin Drug Investig       Date:  2015-04       Impact factor: 2.859

2.  Effective Canadian policy to reduce harms from prescription opioids: learning from past failures.

Authors:  Benedikt Fischer; Jürgen Rehm; Mark Tyndall
Journal:  CMAJ       Date:  2016-11-07       Impact factor: 8.262

Review 3.  Abuse-deterrent formulations, an evolving technology against the abuse and misuse of opioid analgesics.

Authors:  Tammi Schaeffer
Journal:  J Med Toxicol       Date:  2012-12

Review 4.  Will abuse-deterrent formulations of opioid analgesics be successful in achieving their purpose?

Authors:  Bernard Bannwarth
Journal:  Drugs       Date:  2012-09-10       Impact factor: 9.546

5.  Dynamic model of nonmedical opioid use trajectories and potential policy interventions.

Authors:  Wayne Wakeland; Alexandra Nielsen; Peter Geissert
Journal:  Am J Drug Alcohol Abuse       Date:  2015-05-18       Impact factor: 3.829

6.  Development of an Abuse- and Alcohol-Resistant Formulation Based on Hot-Melt Extrusion and Film Coating.

Authors:  Nicole Jedinger; Simone Schrank; Johannes M Fischer; Karlheinz Breinhälter; Johannes Khinast; Eva Roblegg
Journal:  AAPS PharmSciTech       Date:  2015-07-24       Impact factor: 3.246

7.  Formulation optimization of hot-melt extruded abuse deterrent pellet dosage form utilizing design of experiments.

Authors:  Sindhuri Maddineni; Sunil Kumar Battu; Joe Morott; Majumdar Soumyajit; Michael A Repka
Journal:  J Pharm Pharmacol       Date:  2013-08-20       Impact factor: 3.765

8.  A comparison among tapentadol tamper-resistant formulations (TRF) and OxyContin® (non-TRF) in prescription opioid abusers.

Authors:  Suzanne K Vosburg; Jermaine D Jones; Jeanne M Manubay; Judy B Ashworth; Douglas Y Shapiro; Sandra D Comer
Journal:  Addiction       Date:  2013-03-13       Impact factor: 6.526

9.  A practical and ethical solution to the opioid scheduling conundrum.

Authors:  Michael E Schatman; Beth D Darnall
Journal:  J Pain Res       Date:  2013-12-06       Impact factor: 3.133

10.  Extended-release hydrocodone - gift or curse?

Authors:  Daniel Krashin; Natalia Murinova; Andrea M Trescot
Journal:  J Pain Res       Date:  2013-01-10       Impact factor: 3.133

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.